Clinical Trial Detail

NCT ID NCT02910700
Title Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib in Patients With BRAF or NRAS-mutated Metastatic Melanoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

melanoma

Therapies

Nivolumab + Trametinib

Dabrafenib + Nivolumab + Trametinib

Age Groups: senior adult

No variant requirements are available.